Glucose promotes breast cancer aggression and reduces metformin efficacy

References

• Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, Wolff AC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008; 300:2754 - 64; http://dx.doi.org/10.1001/jama.2008.824; PMID: 19088353
   PubMed Web of Science ®Google Scholar
• Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579 - 91; http://dx.doi.org/10.1038/nrc1408; PMID: 15286738
   PubMed Web of Science ®Google Scholar
• Goodwin PJ. Host-related factors in breast cancer: an underappreciated piece of the puzzle?. J Clin Oncol 2008; 26:3299 - 300; http://dx.doi.org/10.1200/JCO.2007.15.4526; PMID: 18612145
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9:88; http://dx.doi.org/10.1186/1471-2458-9-88; PMID: 19320986
   PubMed Web of Science ®Google Scholar
• Hall IJ, Newman B, Millikan RC, Moorman PG. Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 2000; 151:754 - 64; http://dx.doi.org/10.1093/oxfordjournals.aje.a010275; PMID: 10965972
   PubMed Web of Science ®Google Scholar
• Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev 2003; 4:157 - 73; http://dx.doi.org/10.1046/j.1467-789X.2003.00108.x; PMID: 12916817
   PubMedGoogle Scholar
• LeRoith D, Novosyadlyy R, Gallagher EJ, Lann D, Vijayakumar A, Yakar S. Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence. Exp Clin Endocrinol Diabetes 2008; 116:Suppl 1 S4 - 6; http://dx.doi.org/10.1055/s-2008-1081488; PMID: 18777452
   PubMed Web of Science ®Google Scholar
• Rose DP, Haffner SM, Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and white American women. Endocr Rev 2007; 28:763 - 77; http://dx.doi.org/10.1210/er.2006-0019; PMID: 17981890
   PubMed Web of Science ®Google Scholar
• Schapira DV, Kumar NB, Lyman GH, Cox CE. Abdominal obesity and breast cancer risk. Ann Intern Med 1990; 112:182 - 6; http://dx.doi.org/10.7326/0003-4819-112-3-182; PMID: 2297194
   PubMed Web of Science ®Google Scholar
• Shaw RJ. Glucose metabolism and cancer. Curr Opin Cell Biol 2006; 18:598 - 608; http://dx.doi.org/10.1016/j.ceb.2006.10.005; PMID: 17046224
   PubMed Web of Science ®Google Scholar
• Stoll BA. Upper abdominal obesity, insulin resistance and breast cancer risk. Int J Obes Relat Metab Disord 2002; 26:747 - 53; PMID: 12037643
   PubMed Web of Science ®Google Scholar
• Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease?. J Clin Oncol 2008; 26:3310 - 6; http://dx.doi.org/10.1200/JCO.2006.10.3168; PMID: 18612147
   PubMed Web of Science ®Google Scholar
• Goodwin PJ. Insulin in the adjuvant breast cancer setting: a novel therapeutic target for lifestyle and pharmacologic interventions?. J Clin Oncol 2008; 26:833 - 4; http://dx.doi.org/10.1200/JCO.2007.14.7132; PMID: 18281653
   PubMed Web of Science ®Google Scholar
• Hede K. Doctors seek to prevent breast cancer recurrence by lowering insulin levels. J Natl Cancer Inst 2008; 100:530 - 2; http://dx.doi.org/10.1093/jnci/djn119; PMID: 18398091
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008; 109:389 - 95; http://dx.doi.org/10.1007/s10549-007-9654-0; PMID: 17659440
   PubMed Web of Science ®Google Scholar
• Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006; 119:236 - 8; http://dx.doi.org/10.1002/ijc.21812; PMID: 16450399
   PubMed Web of Science ®Google Scholar
• Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29:40 - 6; http://dx.doi.org/10.1200/JCO.2009.27.3011; PMID: 21115865
   PubMed Web of Science ®Google Scholar
• Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat 2010; 123:627 - 35; http://dx.doi.org/10.1007/s10549-010-0990-0; PMID: 20571870
   PubMed Web of Science ®Google Scholar
• Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 2005; 6:103 - 11; http://dx.doi.org/10.1016/S1470-2045(05)01736-5; PMID: 15683819
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ligibel JA, Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009; 27:3271 - 3; http://dx.doi.org/10.1200/JCO.2009.22.1630; PMID: 19487373
   PubMed Web of Science ®Google Scholar
• Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer 2012; 2012:809291; http://dx.doi.org/10.1155/2012/809291; PMID: 22295251
   PubMedGoogle Scholar
• Guastamacchia E, Resta F, Triggiani V, Liso A, Licchelli B, Ghiyasaldin S, Sabbà C, Tafaro E. Evidence for a putative relationship between type 2 diabetes and neoplasia with particular reference to breast cancer: role of hormones, growth factors and specific receptors. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4:59 - 66; http://dx.doi.org/10.2174/1568008043339965; PMID: 15032627
   PubMedGoogle Scholar
• Young CD, Anderson SM. Sugar and fat - that’s where it’s at: metabolic changes in tumors. Breast Cancer Res 2008; 10:202; http://dx.doi.org/10.1186/bcr1852; PMID: 18304378
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Bahl M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, Hood N. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2009; 114:517 - 25; http://dx.doi.org/10.1007/s10549-008-0019-0; PMID: 18437560
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008; 68:10238 - 46; http://dx.doi.org/10.1158/0008-5472.CAN-08-2755; PMID: 19074892
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20:42 - 51; http://dx.doi.org/10.1200/JCO.20.1.42; PMID: 11773152
   PubMed Web of Science ®Google Scholar
• Pollak MN. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2012; 2:778 - 90; http://dx.doi.org/10.1158/2159-8290.CD-12-0263; PMID: 22926251
   PubMed Web of Science ®Google Scholar
• Josefson D. High insulin levels linked to deaths from breast cancer. BMJ 2000; 320:1496; PMID: 10834888
   PubMed Web of Science ®Google Scholar
• Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760 - 74; PMID: 21084729
   PubMedGoogle Scholar
• Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012; 118:1202 - 11; http://dx.doi.org/10.1002/cncr.26439; PMID: 21800293
   PubMed Web of Science ®Google Scholar
• Del Barco S, Vazquez-Martin A, Cufí S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B, Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget 2011; 2:896 - 917; PMID: 22203527
   PubMed Web of Science ®Google Scholar
• Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330:1304 - 5; http://dx.doi.org/10.1136/bmj.38415.708634.F7; PMID: 15849206
   PubMed Web of Science ®Google Scholar
• Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32:1620 - 5; http://dx.doi.org/10.2337/dc08-2175; PMID: 19564453
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006; 66:10269 - 73; http://dx.doi.org/10.1158/0008-5472.CAN-06-1500; PMID: 17062558
   PubMed Web of Science ®Google Scholar
• Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27:3297 - 302; http://dx.doi.org/10.1200/JCO.2009.19.6410; PMID: 19487376
   PubMed Web of Science ®Google Scholar
• Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle 2010; 9:1057 - 64; http://dx.doi.org/10.4161/cc.9.6.10994; PMID: 20305377
   PubMed Web of Science ®Google Scholar
• Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes Care 2006; 29:1990 - 1; http://dx.doi.org/10.2337/dc06-0997; PMID: 16873829
   PubMed Web of Science ®Google Scholar
• Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18:54 - 61; http://dx.doi.org/10.1016/j.gde.2008.02.003; PMID: 18387799
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029 - 33; http://dx.doi.org/10.1126/science.1160809; PMID: 19460998
   PubMed Web of Science ®Google Scholar
• Kroemer G, Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell 2008; 13:472 - 82; http://dx.doi.org/10.1016/j.ccr.2008.05.005; PMID: 18538731
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells. Science 1956; 123:309 - 14; http://dx.doi.org/10.1126/science.123.3191.309; PMID: 13298683
   PubMed Web of Science ®Google Scholar
• Zhivotovsky B, Orrenius S. The Warburg Effect returns to the cancer stage. Semin Cancer Biol 2009; 19:1 - 3; http://dx.doi.org/10.1016/j.semcancer.2008.12.003; PMID: 19162190
   PubMed Web of Science ®Google Scholar
• Quon A, Gambhir SS. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 2005; 23:1664 - 73; http://dx.doi.org/10.1200/JCO.2005.11.024; PMID: 15755974
   PubMed Web of Science ®Google Scholar
• Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209:211 - 5; http://dx.doi.org/10.1084/jem.20120162; PMID: 22330683
   PubMed Web of Science ®Google Scholar
• Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Res 2012; 72:6490 - 501; http://dx.doi.org/10.1158/0008-5472.CAN-12-1653; PMID: 23222299
   PubMed Web of Science ®Google Scholar
• Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009; 8:909 - 15; http://dx.doi.org/10.4161/cc.8.6.7933; PMID: 19221498
   PubMed Web of Science ®Google Scholar
• Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; 11:367 - 76; http://dx.doi.org/10.4161/cc.11.2.18813; PMID: 22189713
   PubMed Web of Science ®Google Scholar
• Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 2009; 8:2031 - 40; http://dx.doi.org/10.4161/cc.8.13.8814; PMID: 19440038
   PubMed Web of Science ®Google Scholar
• Menendez JA, Oliveras-Ferraros C, Cufí S, Corominas-Faja B, Joven J, Martin-Castillo B, Vazquez-Martin A. Metformin is synthetically lethal with glucose withdrawal in cancer cells. Cell Cycle 2012; 11:2782 - 92; http://dx.doi.org/10.4161/cc.20948; PMID: 22809961
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol 2012; 48:R31 - 43; http://dx.doi.org/10.1530/JME-12-0007; PMID: 22355097
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012; 29:1314 - 27; http://dx.doi.org/10.1007/s12032-011-9846-7; PMID: 21301998
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574 - 9; http://dx.doi.org/10.1056/NEJM199602293340906; PMID: 8569826
   PubMed Web of Science ®Google Scholar
• Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 2012; 135:821 - 30; http://dx.doi.org/10.1007/s10549-012-2223-1; PMID: 22933030
   PubMed Web of Science ®Google Scholar
• Menendez JA, Cufí S, Oliveras-Ferraros C, Martin-Castillo B, Joven J, Vellon L, Vazquez-Martin A. Metformin and the ATM DNA damage response (DDR): accelerating the onset of stress-induced senescence to boost protection against cancer. Aging (Albany NY) 2011; 3:1063 - 77; PMID: 22170748
   PubMedGoogle Scholar
• Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A 2013; 110:972 - 7; http://dx.doi.org/10.1073/pnas.1221055110; PMID: 23277563
   PubMed Web of Science ®Google Scholar
• Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status. Cell Cycle 2010; 9:3807 - 14; http://dx.doi.org/10.4161/cc.9.18.13131; PMID: 20890129
   PubMed Web of Science ®Google Scholar
• Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009; 69:7507 - 11; http://dx.doi.org/10.1158/0008-5472.CAN-09-2994; PMID: 19752085
   PubMed Web of Science ®Google Scholar
• Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49:Suppl 2 24S - 42S; http://dx.doi.org/10.2967/jnumed.107.047258; PMID: 18523064
   PubMed Web of Science ®Google Scholar
• Ding WQ, Liu B, Vaught JL, Palmiter RD, Lind SE. Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol Cancer Ther 2006; 5:1864 - 72; http://dx.doi.org/10.1158/1535-7163.MCT-06-0067; PMID: 16891473
   PubMed Web of Science ®Google Scholar